|
[1]NG SC,SHI HY,HAMIDI N,et al.Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century:A systematic review of population-based studies[J].Lancet,2018,390(10114):2769-2778．
|
|
[2]HE Q,LI JD.Epidemiological progress of inflammatory bowel disease[J].J Pract Med,2019,35(18):2962-2966.(in Chinese)何琼，李建栋．炎症性肠病流行病学研究进展[J]．实用医学杂志，2019,35(18):2962-2966．
|
|
[3]CHAO CY,BATTAT R,AL KHOURY A,et al.Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease:Areview article[J].World J Gastroenterol,2016,22(34):7727-7734．
|
|
[4]FENG G,MI M,LI XP,et al.The economic burden and risk factors in inflammatory bowel disease with nonalcoholic fatty liver disease[J].J Clin Hepatol,2018,34(12):2702-2706.(in Chinese)冯巩，弥曼，李雪萍，等．炎症性肠病合并非酒精性脂肪性肝病的经济负担及危险因素[J]．临床肝胆病杂志，2018,34(12):2702-2706．
|
|
[5]SAROLI PALUMBO C,RESTELLINI S,CHAO CY,et al.Screening for nonalcoholic fatty liver disease in inflammatory bowel diseases:A cohort study using transient elastography[J].Inflamm Bowel Dis,2019,25(1):124-133．
|
|
[6]PRINCIPI M,IANNONE A,LOSURDO G,et al.Nonalcoholic fatty liver disease in inflammatory bowel disease:Prevalence and risk factors[J].Inflamm Bowel Dis,2018,24(7):1589-1596．
|
|
[7]GLASSNER K,MALATY HM,ABRAHAM BP.Epidemiology and risk factors of nonalcoholic fatty liver disease among patients with inflammatory bowel disease[J].Inflamm Bowel Dis,2017,23(6):998-1003．
|
|
[8]ZOU ZY,SHEN B,FAN JG.Systematic review with meta-analysis:Epidemiology of nonalcoholic fatty liver disease in patients with inflammatory bowel disease[J].Inflamm Bowel Dis,2019,25(11):1764-1772．
|
|
[9]RESTELLINI S,CHAZOUILLRES O,FROSSARD JL.Hepatic manifestations of inflammatory bowel diseases[J].Liver Int,2017,37(4):475-489．
|
|
[10]SHAMBERG L,VAZIRI H.Hepatotoxicity of inflammatory bowel disease medications[J].J Clin Gastroenterol,2018,52(8):674-684．
|
|
[11]SILVA J,BRITO BS,SILVA I,et al.Frequency of hepatobiliary manifestations and concomitant liver disease in inflammatory bowel disease patients[J].Biomed Res Int,2019,2019:7604939．
|
|
[12]BJRNSSON ES,GU J,KLEINER DE,et al.Azathioprine and 6-mercaptopurine-induced liver injury:Clinical features and outcomes[J].J Clin Gastroenterol,2017,51(1):63-69．
|
|
[13]CONWAY R,LOW C,COUGHLAN RJ,et al.Risk of liver injury among methotrexate users:A meta-analysis of randomised controlled trials[J].Semin Arthritis Rheum,2015,45(2):156-162．
|
|
[14]SHELTON E,CHAUDREY K,SAUK J,et al.New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease[J].Aliment Pharmacol Ther,2015,41(10):972-979．
|
|
[15]ANTEZANA A,SIGAL S,HERBERT J,et al.Natalizumab-induced hepatic injury:A case report and review of literature[J].Mult Scler Relat Disord,2015,4(6):495-498．
|
|
[16]MAHFOUZ M,MARTIN P,CARRION AF.Hepatic complications of inflammatory bowel disease[J].Clin Liver Dis,2019,23(2):191-208．
|
|
[17]DEFILIPPIS EM,KUMAR S.Clinical presentation and outcomes of autoimmune hepatitis in inflammatory bowel disease[J].Dig Dis Sci,2015,60(10):2873-2880．
|
|
[18]CHEN D,LUO S,BEN Q,et al.Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China[J].Eur J Gastroenterol Hepatol,2017,29(5):509-515．
|
|
[19]Inflammatory Bowel Disease Group,Chinese Society of Gastroenterology,Chinese Medical Association.Evidence-based consensus on opportunistic infections in inflammatory bowel disease(republication)[J].Intest Res,2018,16(2):178-193．
|
|
[20]PERRILLO RP,GISH R,FALCK-YTTER YT.American gastroenterological association institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J].Gastroenterology,2015,148(1):221-244.e3．
|
|
[21]LORAS C,GISBERT JP,MNGUEZ M,et al.Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy[J].Gut,2010,59(10):1340-1346．
|
|
[22]HARBORD M,ANNESE V,VAVRICKA SR,et al.The first European evidencebased consensus on extra-intestinal manifestations in inflammatory bowel disease[J].J Crohn Colitis,2016,10(3):239-254．
|
|
[23]NAYMAGON L,TREMBLAY D,ZUBIZARRETA N,et al.The natural history,treatments,and outcomes of portal vein thrombosis in patients with inflammatory bowel disease[J].Inflamm Bowel Dis,2020.[Online ahead of print]
|
|
[24]LIN JN,LIN CL,LIN MC,et al.Pyogenic liver abscess in patients with inflammatory bowel disease:A nationwide cohort study[J].Liver Int,2016,36(1):136-144．
|
|
[25]FOUSEKIS FS,KATSANOS KH,THEOPISTOS VI,et al.Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases:A referral center study[J].BMC Gastroenterol,2019,19(1):48．
|
|
[26]FAGAGNINI S,HEINRICH H,ROSSEL JB,et al.Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases[J].PLo S One,2017,12(10):e0185193．
|
|
[27]CHEN CH,LIN CL,KAO CH.Association between inflammatory bowel disease and cholelithiasis:A nationwide population-based cohort study[J].Int J Environ Res Public Health,2018,15(3):513．
|
|
[28]ZHANG FM,XU CF,SHAN GD,et al.Is gallstone disease associated with inflammatory bowel diseases?A meta-analysis[J].J Dig Dis,2015,16(11):634-641．
|
|
[29]LINDOR KD,KOWDLEY KV,HARRISON ME.ACG clinical guideline:Primary sclerosing cholangitis[J].Am J Gastroenterol,2015,110(5):646-660．
|
|
[30]TABIBIAN JH,ALI AH,LINDOR KD.Primary sclerosing cholangitis,part1:Epidemiology,etiopathogenesis,clinical features,and treatment[J].Gastroenterol Hepatol(N Y),2018,14(5):293-304．
|
|
[31]DYSON JK,BEUERS U,JONES D,et al.Primary sclerosing cholangitis[J].Lancet,2018,391(10139):2547-2559．
|
|
[32]LIU K,WANG R,KARIYAWASAM V,et al.Epidemiology and outcomes of primary sclerosing cholangitis with and without inflammatory bowel disease in an Australian cohort[J].Liver Int,2017,37(3):442-448．
|
|
[33]WEISMLLER TJ,TRIVEDI PJ,BERGQUIST A,et al.Patient age,sex,and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis[J].Gastroenterology,2017,152(8):1975-1984.e8．
|
|
[34]CHANG M,CHANG L,CHANG HM,et al.Intestinal and extraintestinal cancers associated with inflammatory bowel disease[J].Clin Colorectal Cancer,2018,17(1):e29-e37．
|
|
[35]LUNDER AK,HOV JR,BORTHNE A,et al.Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease[J].Gastroenterology,2016,151(4):660-669.e4．
|
|
[36]RAMOS LR,SACHAR DB,DIMAIO CJ,et al.Inflammatory bowel disease and pancreatitis:A review[J].J Crohn's Colitis,2016,10(1):95-104．
|
|
[37]ANTONINI F,PEZZILLI R,ANGELELLI L,et al.Pancreatic disorders in inflammatory bowel disease[J].World J Gastrointest Pathophysiol,2016,7(3):276-282．
|
|
[38]PEZZILLI R,PAGANO N.Benign exocrine pancreatic diseases in inflammatory bowel diseases[J].Dig Dis,2017,35(5):449-453．
|
|
[39]YADAV D,LOWENFELS AB.The epidemiology of pancreatitis and pancreatic cancer[J].Gastroenterology,2013,144(6):1252-1261．
|
|
[40]GARCIA GARCIA DE PAREDES A,RODRIGUEZ DE SANTIAGO E,RODRIGUEZ-ESCAJA C,et al.Idiopathic acute pancreatitis in patients with inflammatory bowel disease:A multicenter cohort study[J].Pancreatology,2020,20(3):331-337．
|
|
[41]KIM JW,HWANG SW,PARK SH,et al.Clinical course of ulcerative colitis patients who develop acute pancreatitis[J].World J Gastroenterol,2017,23(19):3505-3512．
|
|
[42]PEDERSEN JE,NGQUIST LH,JENSEN CB,et al.Risk of pancreatitis in patients with inflammatory bowel disease-a meta-analysis[J].Dan Med J,2020,67(3):A08190427．
|
|
[43]CHEN YT,SU JS,TSENG CW,et al.Inflammatory bowel disease on the risk of acute pancreatitis:A population-based cohort study[J].J Gastroenterol Hepatol,2016,31(4):782-787．
|
|
[44]SRINATH AI,GUPTA N,HUSAIN SZ.Probing the association of pancreatitis in inflammatory bowel disease[J].Inflamm Bowel Dis,2016,22(2):465-475．
|
|
[45]CHEN YL,HSU CW,CHENG CC,et al.Increased subsequent risk of inflammatory bowel disease association in patients with chronic pancreatitis:A nationwide population-based cohort study[J].Curr Med Res Opin,2017,33(6):1077-1082．
|
|
[46]FOUSEKIS FS,THEOPISTOS VI,KATSANOS KH,et al.Pancreatic involvement in inflammatory bowel disease:A review[J].J Clin Med Res,2018,10(10):743-751．
|
|
[47]UEKI T,KAWAMOTO K,OTSUKA Y,et al.Prevalence and clinicopathological features of autoimmune pancreatitis in Japanese patients with inflammatory bowel disease[J].Pancreas,2015,44(3):434-440．
|
|
[48]MARTN-DE-CARPI J,MORICZI M,PUJOL-MUNCUNILL G,et al.Pancreatic involvement in pediatric inflammatory bowel disease[J].Front Pediatr,2017,5:218．
|
|
[49]ROQUE RAMOS L,DIMAIO CJ,SACHAR DB,et al.Autoimmune pancreatitis and inflammatory bowel disease:Case series and review of the literature[J].Dig Liver Dis,2016,48(8):893-898．
|
|
[50]KAWA S,OKAZAKI K,NOTOHARA K,et al.Autoimmune pancreatitis complicated with inflammatory bowel disease and comparative study of type 1 and type 2 autoimmune pancreatitis[J].J Gastroenterol,2015,50(7):805-815．
|
|
[51]LORENZO D,MAIRE F,STEFANESCU C,et al.Features of autoimmune pancreatitis associated with inflammatory bowel diseases[J].Clin Gastroenterol Hepatol,2018,16(1):59-67．
|
|
[52]HART PA,LEVY MJ,SMYRK TC,et al.Clinical profiles and outcomes in idiopathic duct-centric chronic pancreatitis(type 2 autoimmune pancreatitis):The mayo clinic experience[J].Gut,2016,65(10):1702-1709．
|
|
[53]PARK SH,KIM D,YE BD,et al.The characteristics of ulcerative colitis associated with autoimmune pancreatitis[J].J Clin Gastroenterol,2013,47(6):520-525．
|
|
[54]SHEN XG,ZOU DW,LI ZS,et al.Inflammatory bowel disease complicating with pancreatic abnormalities:A single center analysis[J].Chin J Pancreatol,2018,18(3):193-195.(in Chinese)沈祥国，邹多武，李兆申，等．炎症性肠病合并胰腺病变单中心分析[J]．中华胰腺病杂志，2018,18(3):193-195．
|
|
[55]MOSHER CA,BROWN GR,WEIDEMAN RA,et al.Incidence of colorectal cancer and extracolonic cancers in veteran patients with inflammatory bowel disease[J].Inflamm Bowel Dis,2018,24(3):617-623．
|
|
[56]PEDERSEN N,DURICOVA D,ELKJAER M,et al.Risk of extraintestinal cancer in inflammatory bowel disease:Meta-analysis of population-based cohort studies[J].Am J Gastroenterol,2010,105(7):1480-1487．
|
|
[57]JUNG YS,HAN M,PARK S,et al.Cancer risk in the early stages of inflammatory bowel disease in korean patients:A nationwide population-based study[J].J Crohns Colitis,2017,11(8):954-962.
|
DownLoad: